drugset / Trial / NCT03601442

Managed Access Programs for CTL019, Tisagenlecleucel

NCT03601442 ↗

Expanded access Available Novartis Pharmaceuticals

Summary

The purpose of this registration is to list Managed Access Programs (MAPs) related to CTL019, Tisagenlecleucel

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Tisagenlecleucel Cell therapy — —

Indications